YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results New QIAGEN Discovery Platform extends AI into drug discovery workflows QIAGEN builds on more than 25…
QIAGEN N.V. QGEN announced that U.S. laboratories now have access to its complete QIAstat-Dx bloodstream infection portfolio following FDA clearance of a new panel. The new QIAstat-Dx BCID GN Plus AMR Panel identifies gram-negative bacteri…
Company Logo The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digit…
Qiagen (NYSE:QGEN) just received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company's rapid sepsis testing portfolio in a single automated system. Qiagen…
Earlier this week, QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, complementing an existing g…
Company Logo Demand is rising in diagnostics, precision medicine and biopharma research, while nanotechnology, automation and AI unlock targeted therapies and high-throughput workflows. Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic…
Bloodstream infections can trigger sepsis, a life-threatening response to infection; about 1.7 million U.S. adults develop sepsis each year, contributing to at least 350,000 deaths New QIAstat-Dx test identifies 13 gram-negative bacterial…
Compact system offers research laboratories a time-saving and cost-efficient way to automate work still done by hand Reduction in hands-on time of over 80% compared with manual sample processing Third new sample preparation system launched…
QIAGEN N.V. QGEN is well positioned for growth in the upcoming quarters, supported by continued test menu expansion. Meanwhile, strategic partnerships support assay development and create opportunities for recurring consumables revenues ac…
VENLO, Netherlands, September 18, 2026--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shar…
Company Logo AI, Advanced Sequencing and Precision Medicine Drive Genomics Opportunities Across Diagnostics, Drug Development and Preventive Care Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Genomics Market Opportunity, Growth Drivers, Indu…
Company Logo Pharmacogenomics Expands as Multi-Gene Testing, Bioinformatics and Precision Diagnostics Drive Clinical Adoption Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Pharmacogenomics Market Opportunity, Growth Drivers, Industry Trend A…
Bull on Wall Street by Alexander Naumann via Pixabay The S&P 500 Index ($SPX) (SPY) closed up by +1.14% on Thursday, the Dow Jones Industrial Average ($DOWI) (DIA) closed up by +0.61%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.73…
Bullish - green stock market chart with arrow up day trade by Quality Stock Arts via Shutterstock The S&P 500 Index ($SPX) (SPY) is up by +0.86% today, the Dow Jones Industrial Average ($DOWI) (DIA) is up by +0.36%, and the Nasdaq 100 Inde…
Inside NYSE by Orhan Akkurt via Shutterstock The S&P 500 Index ($SPX) (SPY) is up by +0.91% today, the Dow Jones Industrial Average ($DOWI) (DIA) is up by +0.45%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.31%. E-mini S&P futures (ESU…
On August 27, QIAGEN N.V. (NYSE:QGEN) launched QIAsymphony Connect, a new automated platform for clinical nucleic acid extraction aimed at laboratories running liquid biopsy, oncology, and infectious disease tests. The timing is notable. O…
Company Logo The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker deve…
Photo by jarmoluk on Pixabay A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects. Illumina (ILMN), a maker of gene sequ…
Qiagen (QGEN) has drawn fresh attention after Q2 2026 adjusted earnings and net sales came in above consensus, even as estimates had recently drifted lower, and management reaffirmed its full year outlook. The Q2 beat and reaffirmed guidan…
In late August 2026, Qiagen launched QIAsymphony Connect, an IVD-compliant automated nucleic acid extraction platform with FDA and EUDAMED listings, while also announcing a CEO transition to Jon Pratt from September 1 and reporting Q2 2026…
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have added about 5.1% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its…
Company Logo The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%;…
Company Logo Opportunities center on NGS, metagenomic profiling, portable field tests and cloud analytics, driven by viral outbreaks, precision agriculture, biosecurity and demand for early detection. Plant Virome Diagnostics MarketPlant V…
10x Genomics, Inc. TXG recently secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen QGEN subsidiary. The Delaware jury found Parse infringed three patents licensed to Scale Biosciences, uphe…
Qiagen N.V. (NYSE:QGEN) announced on August 10 that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, marking the company's first entry into the U.S. bloodstream infection testing market. Operating on the QIAstat-Dx platform, wh…
[Wooden cubes forming the word PATENT on a document, legal and intellectual property concept.] * Qiagen (QGEN [https://seekingalpha.com/symbol/QGEN]) subsidiary Parse Biosciences will be forced to pay more than $4.8M in damages after a jur…
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on acce…
New IVD automation platform standardizes nucleic acid extraction across diverse assay workflows with improved productivity, sample traceability and process safety Builds on more than 3,300 cumulative placements of the established QIAsympho…
[DNA sample] dra_schwartz/iStock via Getty Images Two parties started formal due diligence on Qiagen (QGEN [https://seekingalpha.com/symbol/QGEN]) as part of the molecular diagnostics provider's strategic review. The due diligence started…
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Jonathan Pratt New title: CEO, Qiagen Previous title: CEO, Filtration Group Qiagen said Mon…
Investing.com -- Qiagen N.V. (NYSE:QGEN) announced Monday that Jonathan M. Pratt will become chief executive officer on September 1, 2026, as the molecular testing company continues discussions with potential buyers. Pratt brings over 25 y…
Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall To assume CEO role on September 1, 2026, succeeding Thierry Bernard QIA…
Shares of Bio-Rad Laboratories BIO have climbed 19.1% in the past month, putting the durability of that momentum in focus. Digital PCR demand and steadier Clinical Diagnostics performance provide support. Yet Life Science demand remains we…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Qiagen (QGEN) has drawn fresh attention after surpassing its own sales and EPS outlook for Q2 2026 and reaffirming full year…
Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company's own ou…
Zillow Group (NASDAQ:Z) delivered a second quarter that beat its own outlook on nearly every line, then turned around and eliminated jobs and reshuffled its leadership team. On the call held August 5, CEO Jeremy Wacksman and newly expanded…